Primary |
Non-small Cell Lung Cancer |
29.2% |
Hypertension |
9.7% |
Constipation |
8.7% |
Pain |
8.5% |
Nausea |
7.8% |
Prophylaxis |
5.6% |
Insomnia |
3.0% |
Diarrhoea |
2.9% |
Back Pain |
2.7% |
Lung Neoplasm Malignant |
2.6% |
Anxiety |
2.4% |
Supplementation Therapy |
2.4% |
Cough |
2.1% |
Chronic Obstructive Pulmonary Disease |
1.9% |
Vomiting |
1.9% |
Diabetes Mellitus |
1.8% |
Gastrooesophageal Reflux Disease |
1.8% |
Pulmonary Embolism |
1.8% |
Hyperlipidaemia |
1.7% |
Hypothyroidism |
1.7% |
|
Death |
22.8% |
Interstitial Lung Disease |
11.3% |
Non-small Cell Lung Cancer |
6.3% |
Cytolytic Hepatitis |
6.0% |
Pulmonary Embolism |
5.0% |
Neoplasm Malignant |
4.6% |
Respiratory Failure |
4.6% |
Disease Progression |
4.0% |
Vomiting |
4.0% |
Dehydration |
3.3% |
Hepatotoxicity |
3.3% |
Deep Vein Thrombosis |
3.0% |
Dyspnoea |
3.0% |
Hyponatraemia |
3.0% |
Convulsion |
2.6% |
Diarrhoea |
2.6% |
Haemoptysis |
2.6% |
Nausea |
2.6% |
Pneumonia |
2.6% |
Renal Failure Acute |
2.6% |
|
Secondary |
Non-small Cell Lung Cancer |
22.3% |
Pain |
11.7% |
Constipation |
11.0% |
Hypertension |
6.5% |
Nausea |
6.3% |
Gastrointestinal Pain |
5.9% |
Product Used For Unknown Indication |
4.1% |
Insomnia |
3.3% |
Anxiety |
3.0% |
Back Pain |
2.8% |
Hyperlipidaemia |
2.6% |
Prophylaxis |
2.6% |
Supplementation Therapy |
2.6% |
Hypothyroidism |
2.4% |
Vomiting |
2.4% |
Depression |
2.2% |
Gastrooesophageal Reflux Disease |
2.2% |
Bronchial Carcinoma |
2.0% |
Lung Adenocarcinoma Metastatic |
2.0% |
Diarrhoea |
1.9% |
|
Hepatic Function Abnormal |
9.3% |
Gastric Ulcer |
8.1% |
Transaminases Increased |
8.1% |
Non-small Cell Lung Cancer |
7.0% |
Pneumonia |
7.0% |
Urinary Tract Infection |
7.0% |
Cytolytic Hepatitis |
5.8% |
Lower Respiratory Tract Infection |
4.7% |
Oedema Peripheral |
4.7% |
Orthostatic Hypotension |
4.7% |
Basal Cell Carcinoma |
3.5% |
Decreased Appetite |
3.5% |
Diarrhoea Haemorrhagic |
3.5% |
Gastritis |
3.5% |
Interstitial Lung Disease |
3.5% |
Large Intestine Perforation |
3.5% |
Pleural Effusion |
3.5% |
Viral Infection |
3.5% |
Visual Acuity Reduced |
3.5% |
Autoimmune Hepatitis |
2.3% |
|
Concomitant |
Non-small Cell Lung Cancer |
17.5% |
Lung Neoplasm Malignant |
15.8% |
Drug Use For Unknown Indication |
12.3% |
Product Used For Unknown Indication |
12.3% |
Multiple Myeloma |
8.8% |
Gastrointestinal Carcinoma |
7.0% |
Deep Vein Thrombosis |
3.5% |
Metastases To Bone |
3.5% |
Nausea |
3.5% |
Prophylaxis |
3.5% |
Transient Ischaemic Attack |
3.5% |
Constipation |
1.8% |
Hypotension |
1.8% |
Mineral Supplementation |
1.8% |
Pain |
1.8% |
Thromboembolism Prophylaxis |
1.8% |
|
Haematoma |
20.0% |
Vision Blurred |
20.0% |
Hypocalcaemia |
10.0% |
Metastasis |
10.0% |
Off Label Use |
10.0% |
Urinary Retention |
10.0% |
Vomiting |
10.0% |
White Blood Cell Count Decreased |
10.0% |
|
Interacting |
Angiogram |
39.3% |
Non-small Cell Lung Cancer |
39.3% |
Bipolar I Disorder |
7.1% |
Depression |
7.1% |
Neoplasm Malignant |
7.1% |
|
Drug Interaction |
38.5% |
Sinus Bradycardia |
38.5% |
Multi-organ Failure |
15.4% |
Electrocardiogram Qt Prolonged |
7.7% |
|